Skip to main navigation
  • Careers
  • Contact Us
Xen 01
  • About Us
    • Management
    • Partnering
    • Board of Directors
  • Pipeline
    • obexelimab (XmAb5871)
    • XmAb7195
    • XmAb14045
    • Plamotamab (XmAb13676)
    • XmAb18087
    • XmAb20717
    • XmAb22841
    • XmAb23104
  • Technology
    • Bispecific Fc Domains
    • Cytotoxic Fc Domains
    • Immune Inhibitor Fc Domains
    • Xtend Fc Domains
    • Publications
  • Clinical Trials
    • Expanded Access Policy
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Analyst Coverage
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Investor FAQs
    • Contact Us
    • Email Alerts

You are here:
Home / Investors / Leerink Partners Roundtable Series: Rare Disease & Oncology

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • Investor FAQs
  • Contact Us
  • Email Alerts

Tools

Shareholder Tools

  • Snaphot
  • Print
  • Share
  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • RSS

Leerink Partners Roundtable Series: Rare Disease & Oncology

Oct 03, 2018 at 10:00 AM EDT

Xencor © Copyright 2020
Scroll to top